Editas Medicine (EDIT) began trading on the Nasdaq on 3 Feb 2016

Editas Medicine is a clinical stage genome editing company. The company is a leader in the nascent field of direct gene editing using CRISPR/Cas9 which has the potential to cure many inherited diseases.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 208
• http://www.editasmedicine.com
• Founded in 2013 
• Headquartered in Cambridge, Massachusetts.

Editas priced 5.9M shares at $16, bottom of indicated range of $16-18.